Compass Therapeutics, Inc.(CMPX)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Below size threshold
Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $0.8M in revenue.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
CMPX Stock Analysis & AI Quality Score
AI stock analysis and institutional research for Compass Therapeutics, Inc. (CMPX), a Healthcare sector company. CMPX is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $0.8m in revenue. Based on the latest XBRL financial filings (Q1 2026), Compass Therapeutics, Inc. reports net income of $-18.3M, free cash flow of $-17.4M. Top institutional holders of CMPX by reported 13-F value include TANG CAPITAL MANAGEMENT, ORBIMED ADVISORS, SUVRETTA CAPITAL MANAGEMENT,, based on the most recent SEC filings. CMPX trades on the Nasdaq exchange and files with the SEC under CIK 1738021. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CMPX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Compass Therapeutics, Inc. directly from SEC EDGAR.
Net Income
Q1 2026
$-18.3M
Free Cash Flow
Q1 2026
$-17.4M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · Pro+Revenue
-100.0% YoYNet Income
-34.7% YoYOperating Income
-28.6% YoYTotal Assets
+56.4% YoYTotal Debt
Op. Cash Flow
-9.6% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $0.00 -100.0% | $850.0K | $0.00 | — | — | — |
| Net Income | $-66.5M -34.7% | $-49.4M -16.2% | $-42.5M -8.3% | $-39.2M +52.3% | $-82.2M -178.6% | $-29.5M |
| Operating Income | $-72.8M -28.6% | $-56.6M -12.4% | $-50.4M -20.9% | $-41.7M +49.1% | $-81.9M -194.4% | $-27.8M |
| Total Assets | $219.6M +56.4% | $140.4M -10.5% | $156.9M -21.4% | $199.6M +29.8% | $153.8M +196.2% | $51.9M |
| Total Debt | — | — | — | — | $0.00 -100.0% | $9.3M |
| Operating Cash Flow | $-49.1M -9.6% | $-44.9M -10.4% | $-40.6M -19.0% | $-34.1M -73.5% | $-19.7M +26.6% | $-26.8M |
AI Insight: CMPX Financial Trends
Equity jumped to $210M in Q3 2025 — likely a capital raise — but operating cash burn accelerated to $17M in Q1 2026, the worst in the series.
• Equity surged from $93M in Q2 2025 to $210M in Q3 2025, signaling a significant capital raise that extended the cash runway.
• Operating losses have widened steadily, reaching $-20M in Q1 2026 versus $-15M in Q2 2024.
• Operating cash outflow hit $-17M in Q1 2026, the largest quarterly burn in the dataset, up from $-11M in Q3 2025.
⚠ Equity has declined from $210M to $186M in two quarters — at current burn rates, runway may be 2–3 years without additional raises.
⚠ No revenue recorded across any quarter; any clinical or partnership milestone generating income would be a key inflection point.
AI Insight: CMPX Ratio Trends
CMPX remains deeply unprofitable with no revenue-generating operations; return metrics are uniformly negative across all periods.
• ROE deteriorated sharply from -30.3% in Q3 2024 to -85.3% in Q2 2025, signaling accelerating equity erosion at peak burn.
• After the Q2 2025 trough, ROE partially recovered to -27.2% in Q3 2025 and -31.9% in Q4 2025, suggesting reduced quarterly spend.
• ROIC reached -90.4% in Q2 2025 before rebounding to -36.6% in Q4 2025, tracking the same burn-rate spike and partial relief.
⚠ Q1 2026 ROE re-widened to -39.3% from -31.9% in Q4 2025 — early sign of renewed burn acceleration worth monitoring.
⚠ OpMargin, NPM, and D/E remain entirely unreported; absence of these metrics limits full assessment of financial health.
Get alerted when CMPX's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Compass Therapeutics, Inc. including:
Top Institutional Holders of CMPX
TANG CAPITAL MANAGEMENT LLC
$88.8M16,790,809 shORBIMED ADVISORS LLC
$80.5M15,219,994 shSUVRETTA CAPITAL MANAGEMENT, LLC
$75.7M14,307,379 shVivo Capital, LLC
$50.5M9,545,466 shBlackRock, Inc.
$50.3M9,506,080 shADAGE CAPITAL PARTNERS GP, L.L.C.
$44.9M8,486,500 shEnavate Sciences GP, LLC
$41.2M7,788,150 shBVF INC/IL
$41.1M7,764,842 shSTATE STREET CORP
$35.4M6,694,976 shVANGUARD CAPITAL MANAGEMENT LLC
$31.9M6,037,175 sh
| Fund | Value | Shares |
|---|---|---|
| TANG CAPITAL MANAGEMENT LLC | $88.8M | 16,790,809 |
| ORBIMED ADVISORS LLC | $80.5M | 15,219,994 |
| SUVRETTA CAPITAL MANAGEMENT, LLC | $75.7M | 14,307,379 |
| Vivo Capital, LLC | $50.5M | 9,545,466 |
| BlackRock, Inc. | $50.3M | 9,506,080 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | $44.9M | 8,486,500 |
| Enavate Sciences GP, LLC | $41.2M | 7,788,150 |
| BVF INC/IL | $41.1M | 7,764,842 |
| STATE STREET CORP | $35.4M | 6,694,976 |
| VANGUARD CAPITAL MANAGEMENT LLC | $31.9M | 6,037,175 |
More Healthcare Companies
View all Healthcare →Put CMPX on your watchlist
Track score changes the day Compass Therapeutics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is CMPX a good stock to buy?
13F Pro's AI-powered analysis of Compass Therapeutics, Inc. (CMPX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for CMPX are available on the CMPX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own CMPX?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling CMPX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Compass Therapeutics, Inc.'s investment landscape.